NewAmsterdam Pharma Company N.V. (NAMS) Net margin 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) net profit margin by fiscal year — reported net income divided by reported revenue.
-905.7%FY2025 · since FY2022: -22.0% → -905.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -905.7% | -375.5 pp |
| FY2024 | -530.3% | +725.5 pp |
| FY2023 | -1255.8% | -1233.7 pp |
| FY2022 | -22.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating marginNAMS Operating cash flowNAMS Free cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →